Breaking News Instant updates and real-time market news.

MRK

Merck

$62.10

0.435 (0.71%)

, VIA

Viacom

$39.55

-0.75 (-1.86%)

10:22
10/13/16
10/13
10:22
10/13/16
10:22

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MRK

Merck

$62.10

0.435 (0.71%)

VIA

Viacom

$39.55

-0.75 (-1.86%)

VIAB

Viacom

$35.12

-0.61 (-1.71%)

AMTD

TD Ameritrade

$35.70

-0.01 (-0.03%)

SCHW

Charles Schwab

$30.95

-0.78 (-2.46%)

TLND

Talend

$22.22

-0.41 (-1.81%)

CSC

CSC

$51.34

-0.14 (-0.27%)

  • 25

    Oct

  • 25

    Oct

  • 03

    Nov

  • 06

    Nov

  • 09

    Nov

  • 10

    Nov

  • 14

    Nov

MRK Merck
$62.10

0.435 (0.71%)

10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
VIA Viacom
$39.55

-0.75 (-1.86%)

09/22/16
TLSY
09/22/16
DOWNGRADE
TLSY
Market Perform
CBS downgraded on likely Viacom merger at Telsey Advisory
As noted earlier, Telsey downgraded CBS (CBS) to Market Perform from Outperform. Analyst Tom Eagan says that CBS will probably merge with Viacom (VIA, VIAB). The analyst believes that it will take "years" for Viacom to be turned around, and he says that Viacom's fiscal 2017 EBITDA will come in 18% below its fiscal 2015 level. The analyst expects the company's credit rating to be downgraded by S&P. CBS target to $57 from $67.
09/20/16
WELS
09/20/16
NO CHANGE
WELS
Viacom dividend likely to be eliminated, says Wells Fargo
Wells Fargo says that the market is expecting Viacom (VIA,VIAB) to cut its dividend by 50%. However, Wells Fargo says that the company will eliminate its entire dividend within tow months from now. The firm says that a 50% cut would enable Viacom to barely make its debt payments for the next year but still leave it "with limited financial visibility running at break-even with no cushion." The firm thinks that the company needs at least some cash cushion. It does not expect the company to merge with CBS (CBS) and keeps an Underperform rating on Viacom.
10/13/16
WELS
10/13/16
UPGRADE
WELS
Market Perform
Viacom upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Marci Ryvicker upgraded Viacom (VIAB) to Market Perform saying she believes shares are close to a floor. A merger with CBS (CBS) does not appear imminent, but if/when it does happen, CBS is unlikely to pay less than $32-$33 per Viacom share in a take-under, Ryvicker tells investors in a research note. The analyst has a $33-$35 price target range for Viacom shares. Ryvicker says that she still "REALLY" likes CBS and is cautious on CBS and Disney (DIS) into the Q3 earnings season.
10/04/16
UBSW
10/04/16
UPGRADE
Target $66
UBSW
Buy
CBS upgraded to Buy at UBS
As reported previously, UBS analyst Doug Mitchelson upgraded CBS (CBS) to Buy from Sell. The analyst sees any deal with Viacom (VIA) as priced into CBS shares already. He also has increased confidence in consensus estimates for CBS and sees further upside if the national TV ad market and CBS' ratings remain strong. Mitchelson raised his price target to $66 from $52 on CBS shares.
VIAB Viacom
$35.12

-0.61 (-1.71%)

10/13/16
BOFA
10/13/16
UPGRADE
BOFA
Buy
Viacom upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Jessica Reif Cohen upgraded Viacom (VIAB) two notches to Buy from Underperform and raised its price target to $44 from $37. The analyst views risk/reward as favorable given a potential turnaround by a new management team, which is almost certain. Cohen said Viacom appears closer to a strategy shift that includes re-programming, re-branding, aggressively extending content into digital outlets, and restoring Paramount to growth and profitability. The analyst expects shares to start pricing in a more robust potential as a standalone entity, or a combination with CBS (CBS).
AMTD TD Ameritrade
$35.70

-0.01 (-0.03%)

09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
10/13/16
BOFA
10/13/16
UPGRADE
Target $43
BOFA
Buy
TD Ameritrade upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded TD Ameritrade (AMTD) to Buy and raised its price target to $43 from $33. The analyst sees upside from higher interest rates given TD Ameritrade's exposure to the curve and from other strategic factors including M&A activity and/or competitive/pricing. Carrier said M&A speculation in the space is picking up and said its plausible for TD Ameritrade to acquire privately held Scottrade and/or E-Trade (ETFC).
09/30/16
RHCO
09/30/16
NO CHANGE
RHCO
TD Ameritrade Scottrade acquisition could be up to 10% accretive, says SunTrust
After news outlets reported that TD Ameritrade is considering buying Scottrade, SunTrust analyst Douglas Mewhirter estimates that the acquisition would be up to 10% accretive to TD Amertrade's fiscal 2017 EPS. The analyst keeps a Buy rating on TD Ameritrade.
SCHW Charles Schwab
$30.95

-0.78 (-2.46%)

09/26/16
MSCO
09/26/16
INITIATION
Target $37
MSCO
Overweight
Charles Schwab initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Michael Cyprys initiated Charles Scwhab with an Overweight and a $37 price target. The analyst believes Charles Schwab is uniquely positioned to generate above peer asset growth driven by retail and institutional channels, migration of client cash to the balance sheet from money market funds, greater leverage to rising rates, and benefits from the Department of Labor's Fiduciary Rule which could drive share shift toward the company's low fee products.
09/26/16
09/26/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apache (APA) initiated with a Neutral at MUFG. 2. Marriott (MAR) was initiated with a Buy at Goldman while the firm initiated La Quinta (LQ) with a Sell. Goldman also initiated Red Rock Resorts (RRR), Hyatt (H), and Wyndham (WYN) with a Neutral. 3. Charles Schwab (SCHW) was initiated with an Overweight at Morgan Stanley while the firm initiated E-Trade (ETFC) and TD Ameritrade (AMTD) with an Equal Weight. 4. Valvoline (VVV) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
UPGRADE
Target $38
BOFA
Buy
Charles Schwab upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Charles Schwab to Buy and raised its price target to $38 from $32. The analyst sees upside from higher interest rates given Schwab's exposure to money markets and portfolio duration and from other strategic factors including M&A activity and/or competitive/pricing. Further, Carrier said Schwab has strong organic growth, less pressure from competition, is well positioned for DOL, and can balance revenue and expense growth.
TLND Talend
$22.22

-0.41 (-1.81%)

08/26/16
WBLR
08/26/16
NO CHANGE
WBLR
Outperform
Investor confusion responsible for Talend pullback, says William Blair
William Blair analyst Bhavan Suri believes Talend delivered "solid" results in its first report as a public company, noting that all its metrics came in ahead of the firm's expectations and above the high end of the preliminary ranges provided in the IPO process. However, Suri attributes the post-earnings pullback in the stock to possible confusion on share count and net income guidance, explaining that consensus mismodeled the company's IFRS share count for the quarter by almost 20M shares, which made its EPS appear to be below expectations even though its net income was above the firm's estimate and at the company's preliminary range. Suri keeps an Outperform rating on Talend, citing its "healthy" Big Data and Cloud momentum.
10/13/16
GSCO
10/13/16
UPGRADE
GSCO
Buy
Talend upgraded to Buy from Neutral at Goldman
Goldman analyst Jesse Hulsing upgraded Talend to Buy and maintained its $31 price target saying the company will benefit from analytic workloads moving to the cloud. Hulsing said Talend is well positioned to benefit from this trend given its technology approach that allows users to take advantage of commodity processing and elasticity and a pricing model that is not tied to core growth. The analyst views the recent share pullback as a buying opportunity for a company with 30%+ subscription growth.
09/26/16
RSBL
09/26/16
INITIATION
Target $30
RSBL
Buy
Talend initiated with a Buy at Rosenblatt
Rosenblatt analyst Marshall Senk initiated Talend with a Buy and a $30 price target.
08/23/16
08/23/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Talend (TLND) initiated with an Equal Weight at Barclays, a Neutral at Goldman, a Neutral at Citi, a Neutral at JPMorgan, and an Outperform at William Blair. 2. BJ's Restaurants (BJRI), Brinker (EAT), Buffalo Wild Wings (BWLD), Chipotle (CMG), McDonald's (MCD), Cheesecake Factory (CAKE), Fogo De Chao (FOGO) were initiated with a Hold at Canaccord while the firm initiated Dave & Buster's (PLAY) and Panera Bread (PNRA) with a Buy. 3. Valero (VLO) and Marathon Petroleum (MPC) were initiated with a Buy at Jefferies, which also started coverage on Phillips 66 (PSX) with a Hold rating. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CSC CSC
$51.34

-0.14 (-0.27%)

10/13/16
SBSH
10/13/16
UPGRADE
Target $61
SBSH
Buy
CSC upgraded to Buy from Neutral at Citi
Citi analyst Ashwin Shirvaikar upgraded CSC and raised his price target for the shares to $61 from $49.
07/14/16
OPCO
07/14/16
NO CHANGE
Target $25
OPCO
Outperform
HP Enterprise price target raised to $25 from $21 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for HP Enterprise (HPE) to $25 from $21 following the company's recent results, and the announcement of the spin-off of its Enterprise Services segment and its subsequent merger with CSC (CSC). The analyst believes HP Enterprise's shares offer "significant upside" as the attractiveness of the remaining business becomes visible post spin-off and reiterates an Outperform rating on the stock.
05/25/16
05/25/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSC (CSC) downgraded to Market Perform at Raymond James by analyst Brian Gesuale, who said the merger with HP Enterprise (HPE) "blows up" his previous beliefs of a $7B business capable of shifting its mix towards higher margin services and a new commercial entity that seemed conducive to takeout. Gesuale recommends taking profits and watching the "chaos" from afar until numbers settle over the next 12 months. 2. Best Buy (BBY) downgraded to Hold at Deutsche Bank with analyst Mike Baker saying he management team transition will make it difficult for the multiple to expand. Baker also said that the retailer's outlook is dependent on industry sales improvements in the second half of year which may not materialize. 3. Express (EXPR) downgraded to Market Perform at BMO Capital based on broader concerns that the macro environment will continue to pressure Express' same-store-sales throughout the year and margin pressure is likely as competitive promotions pick up over the coming months. 4. Bonanza Creek (BCEI) downgraded to Underperform at Imperial Capital by analyst Kim Pacanovsky, who said the company's borrowing base reduction was far more severe than her estimate. 5. Greif (GEF) downgraded to Market Perform at BMO Capital as the firm says that it has doubts about the capabilities of the company's executives other than the CEO, while it's unsure about whether the company's "family dominated board" is capable of facilitating a turnaround. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/16
05/25/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Buy at Jefferies by analyst Laurence Alexander, who said a greater than $130 per share takeover by Bayer (BAYRY) is "highly likely." Alexander said that Monsanto's response to Bayer was far from a full-throated defense and benign enough to open the door for more productive discussions. Bayer, meanwhile, was upgraded to Buy at Commerzbank citing a positive view of the company's potential acquisition of Monsanto. The firm sees the underlying growth potential in agriculture and a 60% likelihood of the merger going through. 2. CSC (CSC) upgraded to Outperform at BMO Capital and to Overweight at Barclays, with analysts citing material synergy opportunities and accretion from the merger with HP Enterprise (HPE). HPE Enterprise was also upgraded to Buy at Cross Research and Needham. Needham analyst Richard Kugele said HP enterprise will receive $1.5B in an immediate cash dividend, transfer $600M of net pension liabilities and a $300M EDS bond, and have $1.6B of the company's debt paid off. 3. Western Digital (WDC) upgraded to Overweight at Barclays by analyst Mark Moskowitz, who said the valuation is too low and valuation multiples can increase over the longer term as the company delivers 3D NAND products and reduces its debt load. 4. Applied Materials (AMAT) upgraded to Buy at Citi by analyst Atif Malik, who raised his 2016 and 2017 water fab equipment outlook to reflect higher China equipment spending. Malik added that China is set to become an important driver for equipment spending over the next five years. 5. Fleetmatics (FLTX) upgraded to Overweight at Pacific Crest with analyst Brad Erickson saying the firm's channel checks indicate the company has dominant mind share as the leader in the fleet management space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

DE

Deere

$101.50

-1.2 (-1.17%)

13:12
12/04/16
12/04
13:12
12/04/16
13:12
Periodicals
Deere could keep climbing, Barron's says »

Deere stock recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$9.81

0.28 (2.94%)

, GME

GameStop

$24.27

-0.37 (-1.50%)

12:57
12/04/16
12/04
12:57
12/04/16
12:57
Periodicals
Corporate tax cut can't save all retailers, Barron's says »

Though President-elect…

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

12:40
12/04/16
12/04
12:40
12/04/16
12:40
Periodicals
Callaway Golf investors should take profits, Barron's says »

It "looks like a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVC

Entravision

12:36
12/04/16
12/04
12:36
12/04/16
12:36
Periodicals
Entravision shares could reach $9, Barron's says »

Hispanic-focused…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GOOG

Alphabet

$750.50

2.58 (0.34%)

, GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

12:26
12/04/16
12/04
12:26
12/04/16
12:26
Periodicals
Barron's picks top ten stocks for 2017 »

Selecting its ten…

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AAPL

Apple

$109.90

0.41 (0.37%)

C

Citi

$56.02

-1.25 (-2.18%)

DAL

Delta Air Lines

$48.31

0.54 (1.13%)

DTEGY

Deutsche Telekom

$15.65

0.14 (0.90%)

MRK

Merck

$61.13

0.37 (0.61%)

NVS

Novartis

$68.17

0.42 (0.62%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

UL

Unilever; also tag UN

$39.67

0.5 (1.28%)

UN

Unilever; also tag UL

$39.47

0.35 (0.89%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 15

    Jan

  • 26

    Jan

  • 08

    Mar

  • 13

    Mar

TWTR

Twitter

$17.93

-0.1 (-0.55%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Periodicals
Early Twitter investor Sacca would 'love' to see the company sold, CNBC reports »

One of the earliest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.